{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:54:16Z","timestamp":1780541656104,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2000,11,1]],"date-time":"2000-11-01T00:00:00Z","timestamp":973036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":4640,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2000,11]]},"DOI":"10.1046\/j.1524-4733.2000.36001.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T23:33:06Z","timestamp":1047511986000},"page":"407-416","source":"Crossref","is-referenced-by-count":18,"title":["Second Line Pharmacological Management of Paroxysmal and Persistent Atrial Fibrillation in France: A Cost Analysis"],"prefix":"10.1016","volume":"3","author":[{"given":"Karen","family":"Moeremans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Aliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"de Chillou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Annemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Le Pen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1046\/j.1524-4733.2000.36001.x_bib1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/0003-4819-120-6-199403150-00001","article-title":"Managing chronic atrial fibrillation: a Markov decision analysis comparing Warfarin, Quinidine, and low-dose Amiodarone","volume":"120","author":"Disch","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1540-8167.1997.tb00841.x","article-title":"Pharmacologic management of atrial fibrillation","volume":"8","author":"Riley","year":"1997","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/WNL.28.10.973","article-title":"Epidemiologic assessment of chronic atrial fibrillation and risk of stroke. The Framingham Study","volume":"28","author":"Wolf","year":"1978","journal-title":"Neurology"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib4","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/0735-1097(96)00049-6","article-title":"Regional left atrial stasis during atrial fibrillation and flutter: Determinants and relation to stroke","volume":"27","author":"Shively","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/hrt.77.4.309","article-title":"Heart failure and atrial fibrillation: current concepts and controversies","volume":"77","author":"Van Den Berg","year":"1997","journal-title":"Heart"},{"issue":"5","key":"10.1046\/j.1524-4733.2000.36001.x_bib6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0025-7125(16)30023-2","article-title":"Supraventricular tachyarrhythmias. Pharmacologic versus nonpharmacologic approaches","volume":"79","author":"Chun","year":"1995","journal-title":"Med Clinics North Am"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0002-9149(91)90828-9","article-title":"Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter","volume":"68","author":"Crijns","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0167-5273(96)02631-9","article-title":"The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenone","volume":"54","author":"Wolk","year":"1996","journal-title":"Int J Cardiol"},{"issue":"5A","key":"10.1046\/j.1524-4733.2000.36001.x_bib9","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/S0002-9149(98)00181-7","article-title":"Acute treatment of atrial fibrillation: Why and when to maintain sinus rhythm","volume":"81","author":"Waktare","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1056\/NEJM198701293160505","article-title":"Decision analysis","volume":"316","author":"Pauker","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib11","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/01.CIR.82.4.1106","article-title":"Efficacy and safety of Quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials","volume":"82","author":"Coplen","year":"1990","journal-title":"Circulation"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1007773901631","article-title":"A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study","volume":"12","author":"Levy","year":"1998","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/archinte.1995.00430090044006","article-title":"Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis","volume":"155","author":"Middlekauff","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1161\/01.CIR.97.13.1231","article-title":"Recent national patterns of warfarin use in atrial fibrillation","volume":"97","author":"Stafford","year":"1998","journal-title":"Circulation"},{"issue":"Suppl. A","key":"10.1046\/j.1524-4733.2000.36001.x_bib15","first-page":"14A","article-title":"Prognosis of individuals with atrial fibrillation","volume":"12","author":"Laupacis","year":"1996","journal-title":"Can J Cardiol"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib16","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0002-9149(97)00082-9","article-title":"Atrial fibrillation follow-up investigation of rhythm management\u2014The AFFIRM study design","volume":"79","author":"Affirm Study","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib17","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation","volume":"154","author":"Atrial Fibrillation investigators","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1161\/01.STR.28.2.311","article-title":"Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke","volume":"28","author":"Kaarisalo","year":"1997","journal-title":"Stroke"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib19","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJM198908103210629","article-title":"Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction","volume":"321","author":"CAST investigators","year":"1989","journal-title":"N Engl J Med"},{"issue":"Part II","key":"10.1046\/j.1524-4733.2000.36001.x_bib20","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/j.1540-8159.1997.tb06117.x","article-title":"Risk of complications of atrial fibrillation","volume":"20","author":"Capucci","year":"1997","journal-title":"PACE"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib21","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/j.1540-8167.1997.tb01005.x","article-title":"Antiarrhythmic drug therapy in the management of atrial fibrillation","volume":"8","author":"Ganz","year":"1997","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0735-1097(92)90003-6","article-title":"Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation","volume":"20","author":"Flaker","year":"1992","journal-title":"J Am Coll Cardiol"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib23","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0735-1097(98)00297-6","article-title":"Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials","volume":"32","author":"Dries","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib24","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/S0735-1097(96)00358-0","article-title":"Improving survival for patients with atrial fibrillation and advanced heart failure","volume":"28","author":"Stevenson","year":"1996","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1046\/j.1524-4733.2000.36001.x_bib25","first-page":"811","article-title":"Anticoagulation in chronic nonvalvular atrial fibrillation: a critical appraisal and meta-analysis","volume":"13","author":"Green","year":"1997","journal-title":"Can J Cardiol"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0002-9343(93)90285-W","article-title":"Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention","volume":"95","author":"Landefeld","year":"1993","journal-title":"Am J Med"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib27","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/archinte.158.15.1669","article-title":"Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation","volume":"158","author":"Eckman","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib28","doi-asserted-by":"crossref","first-page":"66A","DOI":"10.1016\/S0002-9149(97)89120-5","article-title":"Comparison of the safety and efficacy of flecainide versus propafenone in hospital outpatients with symptomatic paroxysmal atrial fibrillation\/flutter","volume":"77","author":"Aliot","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0002-9149(98)00078-2","article-title":"Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation","volume":"81","author":"Kochiadakis","year":"1998","journal-title":"Am J Cardiol"},{"issue":"2Pt1","key":"10.1046\/j.1524-4733.2000.36001.x_bib30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00019053-199712020-00003","article-title":"The use of consensus methods and experts panels in pharmacoeconomic studies","volume":"1","author":"Evans","year":"1997","journal-title":"PharmacoEconomics"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib31","unstructured":"Th\u00e9saurus Vidal SEMP, MediaVidal Havas Medimidia. Paris, France 1998."},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib32","unstructured":"Union des caisses nationales de s\u00e9curit\u00e9 sociale Nomenclature g\u00e9n\u00e9rale des actes professionels. UCANNS. Brussels. Belgium. 1999."},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib33","unstructured":"Vanoverbeke N. Comparison of the direct medical costs associated with stroke in France and Belgium. HEDM\u2014Health Economics and Disease Management\u2014Working paper, HEDM. Meise, Belgium, February 1999."},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib34","first-page":"1307","article-title":"Epid\u00e9miologie et impact \u00e9conomique de l'insuffisance cardiaque en France","volume":"11","author":"Delahaye","year":"1998","journal-title":"Arch Mal Coeur Vaiss"},{"issue":"6","key":"10.1046\/j.1524-4733.2000.36001.x_bib35","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1161\/01.STR.28.6.1138","article-title":"Acute stroke care and rehabilitation: an analysis of the direct costs and its clinical and social determinants","volume":"28","author":"J\u00f6rgensen","year":"1997","journal-title":"The Copenhagen Stroke Study. Stroke"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD investigators","year":"1991","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1046\/j.1524-4733.2000.36001.x_bib37","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1161\/01.STR.29.9.1827","article-title":"Cost-effectiveness of anticoagulation in non-rheumatic atrial fibrillation in the primary prevention of ischemic stroke","volume":"29","author":"Lightowlers","year":"1998","journal-title":"Stroke"},{"issue":"Suppl. P","key":"10.1046\/j.1524-4733.2000.36001.x_bib38","first-page":"2","article-title":"From cost of illness to cost-effectiveness in heart failure","volume":"19","author":"L'evy","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib39","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1161\/01.CIR.95.6.1611","article-title":"A novel method for nonfluoroscopic catheter-based electroanatomical mapping of the heart","volume":"95","author":"Gepstein","year":"1997","journal-title":"Circulation"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib40","doi-asserted-by":"crossref","unstructured":"Pappone C, Lamberti F, Rillo M, et al. Catheter ablation of atrial fibrillation using a nonfluoroscopic system. JACC 1998:850\u20133.","DOI":"10.1016\/S0735-1097(98)81518-0"},{"key":"10.1046\/j.1524-4733.2000.36001.x_bib41","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/j.1540-8167.1995.tb00373.x","article-title":"Nonpharmacological approaches to the treatment of atrial fibrillation and atrial flutter","volume":"6","author":"Baker","year":"1995","journal-title":"J Cardiovasc Electrophysiol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301511700109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301511700109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T08:07:29Z","timestamp":1580976449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301511700109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,11]]}},"alternative-id":["S1098301511700109"],"URL":"https:\/\/doi.org\/10.1046\/j.1524-4733.2000.36001.x","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2000,11]]}}}